COPENHAGEN, Dec. 30, 2011 (GLOBE NEWSWIRE) -- Zealand Pharma A/S (Copenhagen:ZEAL), a Danish biopharmaceutical company dedicated to the discovery and development of innovative peptide drugs, has received EUR 3 (DKK 22.3) million in milestone payments under a license agreement with Helsinn Healthcare for the development of elsiglutide (ZP1846). Elsiglutide is a novel GLP-2 peptide agonist, discovered by Zealand Pharma and licensed to Helsinn Healthcare for the treatment of diarrhea induced by chemotherapy in cancer patients.
